Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 12, 2026
TickeronGET DAILY SIGNALS
PDS Biotechnology (PDSB): Analyst Targets Point to a Potential +350% Move

PDS Biotechnology (PDSB): Analyst Targets Point to a Potential +350% Move

Key Takeaways

  • The central $4.50 price target represents the average of two verified analyst targets for PDSB, spanning $4.00 to $5.00.
  • At current levels near $1.00, hitting that target would mean a substantial advance of roughly 350%.
  • Both analysts rate the shares Buy, with the refocused PDS0301 program cited as the main support for their views.
  • As a clinical-stage, pre-revenue company with limited cash, PDSB faces ongoing financing and dilution risks.
  • The pipeline has narrowed to PDS0301 following the deprioritization of PDS0101, which increases single-asset execution risk.
  • Potential supports include Phase 2 PDS0301 data and a planned Phase 3 trial, while funding needs, execution challenges, and micro-cap volatility stand out as key concerns.

Analyst Targets and the Current Consensus

PDS Biotechnology Corporation (PDSB) focuses on targeted cancer immunotherapies at the clinical stage. The $4.50 central target here is simply the arithmetic mean of two confirmed analyst estimates: B. Riley Securities issued a $4.00 Buy rating on October 29, 2026, while H.C. Wainwright reiterated its $5.00 Buy target on October 15, 2026. The range therefore sits between $4.00 and $5.00.

Both firms remain constructive even after the company’s restructuring. H.C. Wainwright has adjusted targets downward from earlier levels as high as $15 and $7, while B. Riley has moved its figure between $3 and $5 over the past year. In my view, this pattern underscores that the bullish case now hinges primarily on progress with the newer PDS0301 program.

Where the Stock Stands and What Reaching the Target Would Require

In mid-November 2026 the shares traded near $1.00, inside a 52-week range of approximately $0.20 to $1.79. Closing the gap to $4.50 would call for an increase of about 350%, a sizable move with no assurance it will occur. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The path forward rests on clinical execution. Management has shared Phase 2 results for PDS0301, an IL-12 antibody-drug conjugate, in metastatic colorectal cancer with liver metastases. Responses appeared more durable in heavily pretreated patients, and a Phase 3 trial is slated to start around the first quarter of 2027. Strong Phase 3 outcomes could support a higher valuation, though delays or setbacks would weaken that outlook.

Factors That Could Help the Stock Approach the Target

  • Further PDS0301 data readouts and the upcoming Phase 3 trial in metastatic colorectal cancer with liver metastases stand as the most direct potential catalysts.
  • A private placement led by Nant Capital brought industry veteran Patrick Soon-Shiong to the board, which may strengthen both funding access and strategic positioning.
  • A roughly 36% workforce reduction in August 2026 aimed to align costs with the narrowed PDS0301 focus and could help extend the cash runway.
  • Both analysts continue to carry Buy ratings, and B. Riley lifted its target from $3 to $4 in late October 2026, reflecting greater confidence in the updated strategy.

Risks That Could Keep the Target Out of Reach

  • PDSB remains pre-revenue, posting a trailing twelve-month net loss near $33.7 million, so it depends on external capital raises that often lead to dilution.
  • Cash stood at roughly $5.6 million with a current ratio near 0.57, pointing to an immediate need for additional financing that could weigh on the share price.
  • The pipeline is now concentrated on PDS0301 after the company stepped back from PDS0101 and ended the VERSATILE-003 Phase 3 trial.
  • A registration to sell up to 16.5 million shares on behalf of holders, combined with a roughly 31% year-over-year rise in shares outstanding, adds potential supply pressure.
  • As a micro-cap name with a history of sharp moves, including a 2019 reverse split, the stock can react strongly to binary clinical news.

Technical Picture and Market Structure

The stock hovers near the $1.00 level that has served as a focal point in recent trading. The 50-day moving average sits around $0.96 and the 200-day near $0.84, so the price remains above its longer-term trend despite recent softness. The 52-week high near $1.79 marks a key resistance area well below the $4.50 target, while the low near $0.20 represents the broader downside boundary. From what I see, a sustained move back above $1.00 could lift sentiment, yet meaningful progress toward the analyst target would likely need clinical catalysts rather than technical momentum alone.

Time Horizon and Items Worth Watching

Analyst targets generally reflect a roughly 12-month horizon, though timing is never guaranteed. Investors should track the next quarterly update expected in November 2026, along with any details on the PDS0301 Phase 3 design, enrollment progress, and further financing. Regulatory feedback, partnership news, insider or strategic buying, and any analyst target revisions also merit attention. Because the investment case is largely binary, shifts in the clinical timeline can drive sharp moves in either direction.

Using AI Tools in My Research Process

I occasionally turn to Tickeron’s AI Daily Buy/Sell Signals when reviewing names like this. The system applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on evolving market conditions, technical patterns, and data-driven analysis. For an event-driven micro-cap such as PDSB, it offers a practical way to monitor trends alongside fundamental work without replacing it.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PDSB

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


PDSB's RSI Indicator leaves overbought zone

The 10-day RSI Indicator for PDSB moved out of overbought territory on October 14, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In 21 of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PDSB as a result. In 74 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for PDSB turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 43 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

PDSB moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDSB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

PDSB broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 50-day moving average for PDSB moved above the 200-day moving average on November 03, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +19.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where PDSB advanced for three days, in 192 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

The Aroon Indicator entered an Uptrend today. In 80 of 107 cases where PDSB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-24.902) is normal, around the industry mean (3.498). P/E Ratio (-1.922) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. PDSB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PDSB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -18%. PEPG experienced the highest price growth at 77%, while ZURA experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers

Industry Biotechnology

Industry
Pharmaceuticals Major
Address
303A College Road
Phone
+1 800 208-3343
Employees
21
Web
https://www.pdsbiotech.com
Interact to see
Advertisement
The central price target used here is $400 , roughly 35% above Alphabet's latest verified closing price of $295.77 (November 13, 2026). This target is the arithmetic mean of verified analyst price targets reviewed, not a single analyst's forecast; independent data providers report comparable consensus averages in the high-$390s to low-$400s.
Upcoming catalysts: Integration of advertising into AI Overviews and Gemini conversations, the scaling of Gemini 3 and newer models across Search and Cloud, and the commercial ramp of the $32 billion Wiz cloud-security acquisition could all shape sentiment into 2026. Strategic positioning: Alphabet's vertically integrated artificial intelligence (AI) stack — from custom TPU (Tensor Processing Unit) chips to the Gemini models to Google Cloud — supports a durable, cost-advantaged position in the AI build-out.
The TETH exchange-traded fund (ETF) is the 21Shares Ethereum Staking ETF, a spot Ethereum fund listed on Cboe BZX, and it does not carry conventional analyst price targets. The $14 objective used here is a technical milestone discussed in public market commentary — roughly the zone where Ethereum could begin confirming a recovery — not an analyst consensus.
Alphabet (GOOGL) fell roughly 15.3% over the last 30 days, sliding from about $349.22 to $295.77, driven primarily by a post-earnings selloff. The decline followed Alphabet's Q3 2026 results, when earnings per share of $2.12 badly missed the $3.02 consensus estimate.
The central target of $6.70 is the arithmetic mean of seven recent, individually verified analyst price targets, rounded from $6.67. At a latest price near $3.70, reaching $6.70 would require roughly 81% upside — a very large move.